Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... with intermediate or high risk IPSS score, or treatment related MDS. c. CML resistant to tyrosine kinase treatment in a first or ... donate peripheral blood: a. Related donor, 8/8 HLA -matched for HLA-A, -B, C and DR matched or, b. Matched Unrelated Donor ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  2. Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT (RIC HSCT NMD)

    ... condition regimen with UCBT, double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood ... Patients must have a 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a ...

    Clinical Trial last updated 06/13/2016 - 2:18pm.

  3. Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    ... undergoing transplantation of bone marrow from half-matched (haploidentical) donors. This approach has extended the transplant option to patients who do not have matched related or unrelated donors, especially for patients from ethnic minority ...

    Clinical Trial last updated 04/29/2016 - 3:26pm.

  4. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical), unrelated (7/8 or 8/8 allele match) donor, or cord ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  5. Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    ... palifermin improves the results of allogeneic SCT from HLA-matched unrelated donors. Objective: - To see if high doses of ... chemotherapy . Secondary AML, defined as AML related to antecedent myeloid neoplasm or cytotoxic chemotherapy. ...

    Clinical Trial last updated 04/29/2016 - 1:00pm.

  6. Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

    ... myeloid leukemia, or chronic myelogenous leukemia undergoing donor peripheral blood stem cell transplant . Giving chemotherapy ... of induction chemotherapy) Other acute leukemia or related neoplasm (including but not limited to 'biphenotypic', ... the principal investigator Patient with a HLA -matched (HLA-A, B, C, and DRB1 molecularly matched) unrelated donor or ...

    Clinical Trial last updated 06/06/2016 - 2:55pm.

  7. CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

    ... Must have a human leukocyte antigen ( HLA )-matched or single allele-mismatched adult sibling serving as donor Must ... prior therapy are considered to be at high risk for regimen related toxicity associated with fully ablative transplant conditioning, and ...

    Clinical Trial last updated 04/29/2016 - 12:36pm.

  8. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    ... years at initial referral with no available and suitably matched related or unrelated donor . Acute myelogenous leukemia ...

    Clinical Trial last updated 04/29/2016 - 3:51pm.

  9. Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

    ... acid [RNA] binding motif protein 45 [DRB1] molecularly matched) unrelated donor or related donor capable of donating PBSC DONOR: HLA-matched unrelated donors ...

    Clinical Trial last updated 06/13/2016 - 2:29pm.

  10. Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

    ... however, human leukocyte antigen ( HLA )-matched donor availability continues to be a major hurdle. Historically, HLA ... comparable to allo-HCT using more traditional HLA matched related and unrelated donors. However, graft-versus-host disease (GvHD) ...

    Clinical Trial last updated 05/03/2016 - 11:15am.